Lantheus Holdings, Inc. (LNTH) stock

LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value

$101.25−0.35 (-0.34%)

Close on Nov 12, 2026Market cap $6.61BP/E 25.0Yield –

Lantheus EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lantheus's EV/EBITDA was 16.9× on Nov 11, 2026, against 10.7× a year earlier. Over the last 5 years it ranged from 7.1× to 401.7×, with a median of 16.8×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	16.9×	+4.9
2025	Dec 31, 2025	12.0×	+0.9
2024	Dec 31, 2024	11.1×	−37.4
2023	Dec 29, 2023	48.5×	+31.7
2022	Dec 30, 2022	16.8×	−253.3
2021	Oct 29, 2021	270.1×	+223.3
2020	Dec 31, 2020	46.8×	+33.2
2019	Dec 31, 2019	13.6×	+2.6
2018	Dec 31, 2018	11.0×	−1.8
2017	Dec 29, 2017	12.8×	+5.2
2016	Dec 30, 2016	7.6×	+0.7
2015	Dec 31, 2015	6.9×	–